This page uses javascripts, but your browser is not currently supporting JavaScripts. Please turn ON scripting in your web browser. Skip to Content

Buprenorphine
Home What is Buprenorphine? Buprenorphine Products DATA Physician Locator DATA 2000 FAQs Links En Español Physician Waiver Qualifications Waiver Notification Form Ongoing Web-based Trainings Waived Physician WebBoard Update Physician Contact Information Model State Medical Board Policy
Buprenorphine Summits Articles SAMHSA Reports Other Gov't Reports To check on a physician's waivered status, please call the Buprenorphine Information Center at 1.866.287.2728. Nurses Guide to Buprenorphine Online Buprenorphine Course for Counselors

 
Articles

The following scholarly articles offer examples of some of the latest research on important issues related to buprenorphine. Please note that this list is not exhaustive nor necessarily endorsed by SAMHSA, but only an illustration of what is currently being done in buprenorphine research.
Adherence
  • Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients. (2013) Though B-MAT adherence requires increased pharmacy utilization, adherent individuals were shown to use fewer expensive health care services, resulting in overall reduced healthcare expenditure compared to non-adherent patients.
    Journal of Substance Abuse Treatment - use this link to view the abstract.

  • A urinalysis-based comparative study of treatment adherence on buprenorphine and buprenorphine-naloxone combination used as opioid substitution therapy. (2012) The findings of the current study suggest that buprenorphine/naloxone combination has a higher adherence rate as compared to buprenorphine when used for opioid substitution therapy.
    Inovations in Clinical Neuroscience - use this link to view the article.


Dosing
  • Effect of buprenorphine dose on treatment outcome. (2012) The higher buprenorphine dose (16-32 mg per day) predicted better retention in treatment compared with the lower dose (less than 16 mg per day). Retention in treatment predicted less illicit opioid use and the positive urine drug screens for cocaine predicted more illicit opioid use. Strong evidence exists based on 21 randomized clinical trials that the higher buprenorphine dose may improve retention in buprenorphine maintenance treatment.
    Journal of Addictive Diseases - use this link to view the abstract.

  • A clinical trial comparing tapering doses of buprenorphine with steady doses for chronic pain and co-existent opioid addiction. (2010) Over 6 months, the participants with chronic pain and co-existent opioid addiction were more likely to adhere to an opioid replacement protocol than an opioid weaning protocol and that opioid replacement therapy with steady doses of buprenorphine/naloxone is associated with improved pain control and physical functioning.
    Journal of Addiction Medicine - use this link to view the article.


Relapse
  • For prescription opioid dependence, relapses associated with shorter treatment course. (2010) In persons dependent on prescription opioids, tapering with buprenorphine during a 9-month period, whether initially or after a period of substantial improvement, led to nearly universal relapse in the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study.
    Medscape Perspectives on the American Psychiatric Association (APA) 2010 Annual Meeting - use this link to view the article.

  • Predictive factors for relapse in patients on buprenorphine maintenance. (2014) This study identifies relapse risk factors during buprenorphine treatment for opioid dependence. Future research is needed to determine whether modifying these factors may lead to improved treatment outcomes.
    American Journal on Addictions - use this link to view the abstract.


Tapering
  • A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. (2013) This study represents a rigorous experimental evaluation of outpatient buprenorphine stabilization, brief taper, and naltrexone maintenance for treatment of prescription opioid dependence. Results suggest that a meaningful subset of prescription opioid-dependent outpatients may respond positively to a 4-week taper plus naltrexone maintenance intervention.
    Journal of the American Medical Association Psychiatry - use this link to view the abstract.


Usage in Pregnancy
  • Buprenorphine favoured over methadone for opiate addiction in pregnancy. (2010) A study in Maine among women addicted to opiates has found that buprenorphine is safer for neonates than traditional treatment with methadone. This article describes research findings from a paper given at the American College of Obstetricians and Gynecologists' (ACOG) Annual Clinical Meeting.
    Use this link to view the abstract.

  • Buprenorphine use in pregnant opioid users: a critical review. (2013) As regards neonatal outcomes, buprenorphine has the same clinical outcome as methadone, although some newer studies suggest that it causes fewer withdrawal symptoms. These novel findings indicate that buprenorphine is emerging as a first-line treatment for pregnant opioid users.
    CNS Drugs - use this link to view the abstract.

  • Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. (2013) Findings suggest no obvious significant adverse maternal or neonatal outcomes related to the use of buprenorphine plus naloxone for the treatment of opioid dependence during pregnancy. These initial findings underscore the need for future research to systematically examine the relative safety and effectiveness of buprenorphine plus naloxone for mother, fetus, and child.
    American Journal on Addictions - use this link to view the abstract.


Youth
  • Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth. (2008) This clinical trial evaluates the efficacy of continuing Buprenorphine-Naloxone for 12 weeks versus detoxification for opioid-addicted youth. The number of patients younger than 18 years was too small to analyze separately, but overall, patients in the detox group had higher proportions of opioid-positive urine test results at weeks 4 and 8 but not at week 12.
    Journal of the American Medical Association - use this link to view the article.

  • Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial.(2010) Extended buprenorphine-naloxone treatment relative to brief detoxification is cost effective in the U.S. health care system for the outpatient treatment of opioid-dependent youth.
    Addiction - use this link to view the article.

 


Go to U.S. Department of Health and Human Services
Home | Accessibility | Privacy | Disclaimer | SAMHSA
Department of Health & Human Services | USA.gov

* Adobe™ PDF formatted files require the Adobe™ Reader to properly read them. Use this link to download this FREE program.

Go to Division of Pharmacologic Therapies